Paper Review Records
All Paper Review Records
16 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
973
days
Decisional conflict among patients with prostate cancer considering germline testing
Authors
Liam Gima-Lange; Kelly Gordon; Barry Tong; Amie Blanco; Daniel H. KwonShow moreShow less
Affiliations
1. Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, USA; 2. Cancer Genetics and Prevention Program, University of California San Francisco, San Francisco, USA; 3. Department of Medicine, University of California San Francisco, San Francisco, USAShow moreShow less
220
days
BRCA2 reversion mutations as a resistance mechanism to olaparib in patients with BRCA2 -mutated mCRPC: a case series
Authors
Kohji Takemura; Ayumi Abe; Kazushige Sakaguchi; Shinji Urakami; Masami Arai; Yuji MiuraShow moreShow less
Affiliations
1. Department of Medical Oncology, Toranomon Hospital, Tokyo, Japan; 2. Department of Advanced Medical Development, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan; 3. Clinical Genetics Center, Toranomon Hospital, Tokyo, Japan; 4. Department of Clinical Genetics, Graduate School of Medicine, Juntendo University, Tokyo, Japan; 5. Department of Urology, Toranomon Hospital, Tokyo, Japan; 6. Department of Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, JapanShow moreShow less
77
days
Awareness of hereditary breast cancer and readiness for genetic testing among newly diagnosed patients with breast cancer in Nigeria: a multicentre study
Authors
Funmilola O. Wuraola; Jenine Ramruthan; Victoria L. Mango; Nneka Sunday-Nweke; Olayide Agodirin; Anna Dare; Adewale A. Aderounmu; Mary Ogunyemi; Boladuro Olawale; Saheed Lawal; Anna T. Santiago; Olalekan Olasehinde; Adewale O. Adisa; Emma Reel; Olusegun I. Alatise; Tulin D. CilShow moreShow less
Affiliations
1. Department of Surgery, Faculty of Clinical Sciences, Obafemi Awolowo University, Ile-Ife, Nigeria; 2. African Research Group for Oncology, Obafemi Awolowo University Teaching Hospitals Complex, Ile-Ife, Nigeria; 3. Department of General Surgery, Princess Margaret Cancer Centre - University Health Network, Toronto, Canada; 4. Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, USA; 5. Department of Surgery, Alex Ekwueme Federal University Teaching Hospital, Abakaliki, Nigeria; 6. Department of Surgery, University of Ilorin, Ilorin, Nigeria; 7. Department of Surgery, University of Toronto, Toronto, Canada; 8. Department of Surgery, Dalla Lana School of Public Health, Toronto, Canada; 9. Department of Biostatistics, University Health Network, Toronto, CanadaShow moreShow less
51
days
Trends in the uptake of nipple sparing mastectomy in BRCA1/2 , PALB2 and other pathogenic variant carriers undergoing risk reducing mastectomy
Authors
Marya Alsuhaibani; Amel Melanson; Alex Viezel-Mathieu; Tassos Dionisopoulos; Mark Basik; Jean Francois Boileau; Karyne Martel; Sarkis Meterissian; Joshua Vorstenbosch; Victor Villareal-Corpuz; William D. Foulkes; Ipshita Prakash; Stephanie M. WongShow moreShow less
Affiliations
1. Department of Surgery, McGill University, Montreal, Canada; 2. Stroll Cancer Prevention Centre, Jewish General Hospital, Montreal, Canada; 3. Department of Plastic and Reconstructive Surgery, McGill University, Montreal, Canada; 4. Department of Oncology, McGill University, Montreal, Canada; 5. Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Canada; 6. Department of Human Genetics, McGill University, Montreal, Canada; 7. Segal Cancer Centre, Jewish General Hospital, Montreal, CanadaShow moreShow less
119
days
Barriers and facilitators of adherence to cancer prevention in Lynch Syndrome: an integrative review
Authors
Marjorie Matekwa; Margaret H. White; Janet H. Van Cleave; Veronica J. Brady; Carina KatigbakShow moreShow less
Affiliations
1. Cizik School of Nursing, The University of Texas Health Science Center at Houston (UTHealth Houston), Houston, USAShow moreShow less
103
days
The psychosocial impact of receiving a polygenic risk score informing risk of prostate cancer
Authors
Matthew Hogben; Emma Hainsworth; Barbara Benton; Jana McHugh; Kathryn Myhill; Eva McGrowder; Reshma Rageevakumar; Denzil James; Sarah Benafif; Elizabeth C. Page; Rosalind A. Eeles; Emma Rowland; Elizabeth K. BancroftShow moreShow less
Affiliations
1. Oncogenetics Research Team, The Royal Marsden NHS Foundation Trust, London, UK; 2. Oncogenetics Research Team, The Institute of Cancer Research, London, UK; 3. University College London Hospitals NHS Foundation Trust, London, UK; 4. Florence Nightingale Faculty of Nursing, Midwifery & Palliative Care, King’s College London, London, UKShow moreShow less
FAQ
How long does Hereditary Cancer in Clinical Practice take to review a manuscript?
As of 2026-11-19, CrushSCI has 16 complete review records for Hereditary Cancer in Clinical Practice. The fastest paper went from submission to acceptance in 19 days (Association analysis of germline variants in GEN1 with a susceptibility to prostate cancer in Polish men, received 2026-05-13, accepted 2026-06-01); the slowest took 973 days. The average is 181.1 days and the median is 113.5 days.
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
